

PN401

Chemical Properties

CAS No.:	4105-38-8
Formula:	C ₁₅ H ₁₈ N ₂ O ₉
Molecular Weight:	370.31
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).

Biological Description

Description	PN-401 is a synthetic uridine pro-drug that is converted to uridine in vivo. Uridine, a pyrimidine nucleotide, has been used in a variety of diseases including depressive disorders and inherited myopathies.
-------------	--

Solubility Information

Solubility	Water: Insoluble DMSO: Soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.700 mL	13.502 mL	27.004 mL
5 mM	0.540 mL	2.700 mL	5.401 mL
10 mM	0.270 mL	1.350 mL	2.700 mL
50 mM	0.054 mL	0.270 mL	0.540 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Saydoff, Joel A.; Garcia, Rolando A. G.; Browne, Susan E.; Liu, Liansheng; Sheng, Jin; Brennehan, Denise; Hu, Zhongyi; Cardin, Sylvain; Gonzalez, Alexis; von Borstel, Reid W.; Gregorio, Jason; Burr, Holly; Beal, M. Flint. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. *Neurobiology of Disease* (2006), 24(3), 455-465. CODEN: NUDIEM ISSN:0969-9961. CAN 146:266494 AN 2006:1245538
2. Doroshow, James H.; McCoy, Sheryl; Macdonald, John S.; Issell, Brian F.; Patel, Taral; Cobb, Patrick W.; Yost, Kathleen J.; Abbruzzese, James L. Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. *Investigational New Drugs* (2006), 24(6), 537-542. CODEN: INNDDK ISSN:0167-6997. CAN 146:414364 AN 2006:834313
3. Saif, Muhammad Wasif; Borstel, Reid. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. *Cancer Chemotherapy and Pharmacology* (2006), 58(1), 136-142. CODEN: CCPHDZ ISSN:0344-5704. CAN 145:327796 AN 2006:375032
4. Garcia, Rolando A. G.; Liu, Liansheng; Hu, Zhongyi; Gonzalez, Alexis; von Borstel, Reid W.; Saydoff, Joel A. Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. *Brain Research* (2005), 1066(1-2), 164-171. CODEN: BRREAP ISSN:0006-8993. CAN 144:81045 AN 2005:1319808

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481